Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

146 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Characterization of Vero cells.
Swanson SK, Mento SJ, Weeks-Levy C, Brock BD, Kowal KJ, Wallace RE, Ritchey MB, Cano FR. Swanson SK, et al. J Biol Stand. 1988 Oct;16(4):311-20. doi: 10.1016/0092-1157(88)90019-4. J Biol Stand. 1988. PMID: 3198660
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.
Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, Knoll A, Getrajdman G, Kowal KJ, Jarnagin WR, Fong Y. Kemeny N, et al. Hum Gene Ther. 2006 Dec;17(12):1214-24. doi: 10.1089/hum.2006.17.1214. Hum Gene Ther. 2006. PMID: 17107303 Clinical Trial.
Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.
Nemunaitis J, Bohart C, Fong T, Meyer W, Edelman G, Paulson RS, Orr D, Jain V, O'Brien J, Kuhn J, Kowal KJ, Burkeholder S, Bruce J, Ognoskie N, Wynne D, Martineau D, Ando D. Nemunaitis J, et al. Cancer Gene Ther. 1998 Sep-Oct;5(5):292-300. Cancer Gene Ther. 1998. PMID: 9824048 Clinical Trial.
Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.
Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, Bruce J, Ognoskie N, Wynne D, Pike M, Kowal K, Merritt J, Ando D. Nemunaitis J, et al. Cancer Gene Ther. 1999 Jul-Aug;6(4):322-30. doi: 10.1038/sj.cgt.7700019. Cancer Gene Ther. 1999. PMID: 10419050 Clinical Trial.
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
Graham JS, Plummer R, McCoy C, Kowal K, Wiesinger H, Detjen K, Calvert H, Wiedenmann B, Cassidy J. Graham JS, et al. Eur J Cancer. 2008 Oct;44(15):2162-8. doi: 10.1016/j.ejca.2008.06.006. Epub 2008 Jul 22. Eur J Cancer. 2008. PMID: 18653327 Clinical Trial.
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Scott EN, Thomas AL, Molife LR, Ahmed S, Blagden S, Fong PC, Kowal K, McCoy C, Wiesinger H, Steward W, De Bono J. Scott EN, et al. Cancer Chemother Pharmacol. 2009 Jul;64(2):425-9. doi: 10.1007/s00280-009-0968-y. Epub 2009 Mar 12. Cancer Chemother Pharmacol. 2009. PMID: 19280191 Clinical Trial.
146 results
Jump to page